Lupus & antiphospholipid syndrome
Beyond the surface: soluble SIGLEC-1 as a clinically applicable type I IFN biomarker
Authors' conclusion
Our study supports sSIGLEC-1 as a reliable and scalable biomarker of IFN-I activity in SLE.
Study context
- Population
- SLE patients and blood donors as controls23 patients over 57 visits longitudinally
- Participants
- 61 vs 100
- Comparison
- sSIGLEC-1 vs mbSIGLEC-1 as IFN-I biomarkers in SLE
- SLEn = 61
- Blood donorsn = 100reference
- Outcome
- sSIGLEC-1 threshold (ROC)
Methodological detailsproof-of-concept, prospective, longitudinal, cohort-specific threshold by ROC analysis
- Proof-of-concept
- Prospective
- Longitudinal
- Cohort-specific threshold by ROC analysis
Performance
As reported in the abstract
sSIGLEC-1 threshold
4.55 ng/ml
Sensitivity
70.49%
Specificity
90%
Further findings
Cross-sectional correlations of sSIGLEC-1
- With mbSIGLEC-1, r (P < 0.001)
- 0.67
- With BILAG, r (P = 0.004)
- 0.37
- With SLEDAI, r (P = 0.005)
- 0.36
- With IFN-α, r (P = 0.006)
- 0.35
- With IP-10, r (P < 0.001)
- 0.57
- Similar results for mbSIGLEC-1
Sensitivity by disease activity
- Moderate activity, sSIGLEC-1
- 76%
- Moderate activity, mbSIGLEC-1
- 84%
- Severe activity, both
- 100%
Longitudinal correlation of changes in BILAG with changes in biomarker
- sSIGLEC-1, r (P = 0.014)
- 0.36
- mbSIGLEC-1, r (P = 0.009)
- 0.38
- 23 patients over 57 visits
Flare prediction (27 patients with quiescent disease, 180 days)
- Neither sSIGLEC-1 nor mbSIGLEC-1 showed significant results
Original publication
Beyond the surface: soluble SIGLEC-1 as a clinically applicable type I IFN biomarker. Rheumatology (Oxford). Published 18 January 2026. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →